Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 7/20 | 0.33 |
| ▸ | THRB | P10828 | 6/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.31 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6791724 | 0.93 | CNR1 (0.34) | SIGMAR1TGFBR1THRBMAPK14CNR1 | |
| SCHEMBL4260846 | 0.79 | SIGMAR1 (0.36) | SIGMAR1PARP10PARP11 | |
| SCHEMBL6792527 | 0.78 | SIGMAR1 (0.33) | SIGMAR1TGFBR1PARP10PARP11 | |
| Trifluoroacetic Acid SCHEMBL6795002 | 0.78 | SIGMAR1 (0.34) | SIGMAR1TGFBR1THRBMAPK14PARP10 | |
| SCHEMBL6794644 | 0.77 | MAOA (0.38) | SIGMAR1 | |
| SCHEMBL5228957 | 0.75 | CCNA2 (0.42) | SIGMAR1 | |
| SCHEMBL4260865 | 0.73 | MAPKAPK2 (0.41) | PARP10PARP11 | |
| SCHEMBL6794606 | 0.73 | CCNA2 (0.40) | SIGMAR1 | |
| SCHEMBL4263111 | 0.72 | SIGMAR1 (0.32) | SIGMAR1 | |
| SCHEMBL6793448 | 0.72 | BRD4 (0.36) | PIM1PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | SIGMAR1 4084/4885TGFBR1 4744/4885THRB 2076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.